Novartis AG ADR (NVS)vsPOMDOCTOR LIMITED American Depositary Shares (POM)
NVS
Novartis AG ADR
$151.72
-0.55%
HEALTHCARE · Cap: $291.32B
POM
POMDOCTOR LIMITED American Depositary Shares
$0.97
-5.15%
HEALTHCARE · Cap: $8.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 14076% more annual revenue ($56.69B vs $399.92M). NVS leads profitability with a 22.5% profit margin vs -53.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
POM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.9%
Fair Value
$92.92
Current Price
$151.72
$58.80 premium
Intrinsic value data unavailable for POM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
17.2% revenue growth
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : POM
The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : POM
The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while POM is a growth play — different risk/reward profiles.
POM is growing revenue faster at 17.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →POMDOCTOR LIMITED American Depositary Shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?